SubscribeThe Drug Information Association (DIA) will host Ethical, Practical and Regulatory Issues in Pediatric Clinical Trials October 25- 26 at the Washington D.C. Marriott Hotel.
There is much debate about the conduct of clinical trials in the pediatric population. The debate is mostly focused on how to balance the need for appropriately investigated medicines for children with the many ethical, practical and regulatory issues that conducting clinical trials in the pediatric population involves. This program will explore these issues in the light of recent legislation and industry best practices.
Sessions on the agenda will include presentations by Klaus Rose, M.D., M.S., head of pediatrics, Clinical Development and Medical Affairs, Novartis Pharma AG and Mary Dianne Murphy, M.D., director of the Office of Pediatric Therapeutics, OC, FDA. Additional topics such as pediatric drug study initiatives in the U.S. and EU, Best Pharmaceuticals for Children Act, Pediatric Research Equity Act, safety concerns, and recruitment and retention challenges will be discussed.
Professionals who will benefit from this program include clinical investigators in academia and industry, investigative site personnel, regulatory affairs personnel involved in clinical safety and pharmacovigilance, and those interested in health policy and clinical research.
The program brochure is available at http://www.diahome.org/Content/Events/05036.pdf. For more information contact Jolene.McNeil@diahome.org or to register online visit http://www.diahome.org/docs/Events/Events_search_detail.cfm?EventID=05036.
HORSHAM, Pa. September X, 2005